🔓 Unlock the full profile of David Bredt (Rapport Therapeutics), including verified contact details, financial insights, and professional associations.
See David Bredt Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: dav*****@rap******.com
Mobile: 71333*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- David Bredt is the Founder and Chief Scientific Officer (CSO) of Rapport Therapeutics, a company focused on developing innovative therapies for patients suffering from neurological disorders.
- Rapport Therapeutics was founded in March 2023 and operates out of San Diego, California. The company aims to address significant unmet needs in the neurotherapeutics space.
- Prior to founding Rapport Therapeutics, Bredt served as the Global Head of Discovery Neuroscience at Johnson & Johnson from March 2011 until March 2021, where strategic leadership was provided in neuroscience research initiatives.
- Before the role at Johnson & Johnson, Bredt was the Vice President of Neuroscience Discovery and Clinical Research at Eli Lilly from August 2004 to February 2011, contributing to numerous advancements in the field of neuroscience.
- Bredt started their academic career as a Professor of Physiology at the University of California, San Francisco (UCSF) in January 1994, where significant contributions to neuroscientific research were made.
- Under Bredt's leadership, Rapport Therapeutics has seen a notable market capitalization of $388.7 million within a year of establishment.
- Rapport Therapeutics has demonstrated growth in headcount, indicating an expanding team and increasing capacity to meet its research and development goals.
- With a presence on reputable platforms such as NASDAQ under the symbol RAPP, Rapport Therapeutics is positioned to attract potential investors and stakeholders in the biotech community.
- Throughout Bredt's career, a strong emphasis has been placed on advancing scientific understanding and therapeutic options in neuroscience, driving innovation and improving patient outcomes.